Benefit-Risk Assessment Based on Number Needed to Treat and Number Needed to Harm: Atogepant vs Calcitonin Gene–Related Peptide Monoclonal Antibodies (P5-12.007)
Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available
10.1212/wnl.0000000000204970